Insertional mutagenesis following gene therapy with gammaretroviral vectors can cause the development of lymphoproliferation in children with X-linked severe combined immunodeficiency. In experimental studies, recombinant adeno-associated virus (rAAV) vectors have also been reported to increase susceptibility to carcinogenesis. The possibility of vector-induced transformation in quiescent ocular cells is probably significantly lower than in mitotically active cells, but given the increasing number of clinical applications of rAAV and lentiviral vectors for ocular disease, a specific assessment of their oncogenic potential in the eye is important. In this study, we investigated the effect of rAAV2/2 and integrating HIV-1 vectors upon the incidence of ocular neoplasia in p53 tumour-suppressor gene-knockout (p53 À/À ) mice, which are highly susceptible to intraocular malignant transformation. Subretinal injections of high titre rAAV2/2 or integrating HIV-1 vectors induced no tumours in p53 À/À or p53 +/À animals, nor significantly affected their natural longevity. We conclude that any insertional events arising from subretinal delivery of these vectors appear insufficient to cause intraocular malignancy, even in highly susceptible animals. These findings support the continued development of these vectors for ocular applications.
INTRODUCTION
In the past decade, the use of gene therapy as a clinical therapeutic option has come of age. Successful gene supplementation trials for monogenic diseases in various organ systems have shown the feasibility of the concept of gene therapy and have encouraged the development of treatments for more challenging diseases. One of the first gene therapy protocols that showed a lasting therapeutic benefit involved the use of a gammaretroviral vector to deliver the common g-chain gene (IL2RG) into the haematopoietic stem cells of children with lethal X-linked severe combined immunodeficiency (X-SCID). 1, 2 In the majority of patients a restoration of the immune system was observed, resulting in substantially increased longevity, and most treated patients are still alive today. However, in recent X-SCID gene therapy trials several cases of iatrogenic acute lymphoblastic leukaemia were reported after ex vivo retroviral transduction of the bone marrow cells. 3 Detailed molecular and genetic analyses demonstrated integration of the gammaretroviral genome into the regulatory region of the host LMO2 proto-oncogene, directly implicating the vector in the oncogenic process. 4 Concerns have also been raised by several in vivo studies regarding the possibility of pro-oncogenic events arising from recombinant adeno-associated virus (rAAV) vectormediated gene transfer to hepatocytes, concerns that are supported by vector integration site analyses. [5] [6] [7] [8] Insertional mutagenesis (IM) is a risk associated with the transposition of genetic material. The ectopic integration of DNA arising from the use of integrating viral vectors may disrupt chromatin or gene structure, thereby altering gene transcription, regulation and/or coding sequences. Of particular concern is the upregulation of endogenous proto-oncogenes, often as a consequence of promoter/enhancer sequences in the vector genome influencing the expression level of the whole gene, or driving expression of a truncated gene. rAAV integration studies in the mouse liver reported that a high frequency (53-72%) of integration events occurred in transcribed regions. 9, 10 A number of integration hot-spots in the mouse genome was identified, the most prominent being rRNA gene repeats. Those studies also identified integrations (3.5%) near or within cancer-related genes. A study in dividing human cells in vitro showed that integration does occur with a slight preference for transcription units (38.8% vs 34.8% calculated random occurrence). 11 Again, rRNA repeats were identified as hot-spots (8%), but no integration frequency near cancer-related genes was reported. Both the studies also found a preference to integrate in or near gene regulatory sequences. The literature on the site preference of lentiviral integration is more extensive still, generally, showing a bias towards integration into active genes and into the 5¢ regulatory regions of genes throughout the genome in mitotically active cells in vitro. 12, 13 Recent work points towards there being less integration preference for active regions in postmitotic rodent cells in vivo, with integration instead being near random, and of uniform frequency into genes and gene spare long interspersed nuclear elements. 14 Thus far, IM leading to malignancies in patients has only been described in dividing cells of the haematopoietic system. It remains to be determined, however, whether naturally quiescent cells, including photoreceptor (PR) cells or the essentially quiescent retinal pigment epithelium (RPE) in the retina are similarly at risk, as non-dividing cells are thought to require more than a single mutagenic event.
In recent clinical trials, gene supplementation therapy using rAAV vectors has shown promise for the treatment of a form of severe earlyonset retinal degeneration due to mutations in the RPE65 gene, [15] [16] [17] and ophthalmic clinical trials using integrating lentiviruses have very recently been initiated (Clinicaltrials.gov identifiers NCT01301443 and NCT01367444). The clinical success of the RPE65 trials, combined with the increasing number of successful pre-clinical studies using rAAV [18] [19] [20] [21] or lentiviruses, [22] [23] [24] [25] [26] [27] [28] suggest that more retinal gene therapy clinical trials are likely to start in the near future. It is, therefore, crucial to determine the oncogenic potential of these gene delivery vehicles in the context of the retina. However, this aspect of gene therapy safety has not been specifically evaluated in detail.
AAV is a parvovirus, which is dependent on other viruses for replication in the host. Although the wild-type virus efficiently integrates in a specific location in the human genome (AAVS1 on chromosome 19), 29 integration of rAAV genomes is typically passive, of low frequency and largely random. [30] [31] [32] The vast majority of rAAV vector genomes remain as episomes in the host cell nucleus, with only an estimated 0.5% of genomes integrating into the host genome, 33 probably at pre-existing chromosomal breaks. 34 However, as doses ranging from 10 11 to 10 12 virus particles may be administered to the human eye, 15, 35 this small fraction of integrating vector genomes potentially equates to a substantial number of integration events. Chromosomal integration by recombinant lentiviral vectors on the other hand, similar to the retroviruses used in the X-SCID trials, is typically an active, highly efficient integrase-driven process, suggesting that these vectors are prone to cause mutagenic events.
In numerous experimental studies thus far, there have been no reports of ocular malignancies after subretinal, intravitreal or intracameral injection of rAAV or lentiviral vectors, and the three current RPE65 gene supplementation therapy trials have not yet reported any acute safety concerns after subretinal administration of rAAV vectors. However, this may in part be a reflection of the shorter lifespan of laboratory animals limiting the follow-up period post treatment, or be biased by the relatively short durations of many experimental studies and the limited follow-up in current ocular trials. The two ophthalmic clinical trials using lentiviral vectors are at an even earlier stage, and safety data are currently awaited. Duration is also of relevance as the incidences of many human tumours increase substantially with longevity. Notably, even the transformation events that occurred after retroviral gene transfer treatment of X-SCID patients did not result in detectable malignancy until 30 months after treatment, 3 despite the fact that haematopoietic stem cells divide readily and frequently, even in the absence of transformation. Furthermore, the cumulative total number of subjects treated so far in the ophthalmic trials is relatively low. [15] [16] [17] These factors therefore make it challenging, at present, to determine the clinical risk of vector-induced ocular malignant transformation.
To assess the risk of malignant transformation of retinal cells due to viral gene therapy, we therefore injected a range of different high-titre vectors in mice deficient in the tumour-suppressor gene p53 (also known as Trp53), 36, 37 and performed extended follow-up. As PRs do not naturally divide and RPE cells are usually quiescent, the induction of an oncogenic phenotype in these cell types is likely to require more than a single mutagenic event. p53-deficient mice already contain a 'second' mutagenic pro-oncogenic mutation, potentially allowing for the earlier detection of the effects of a primary transforming mutation arising from vector integration. They are also established to be more prone to non-ocular tumour formation, 38 and we establish in this current study to also have a greater propensity for intraocular oncogenesis. High-titre vectors (rAAV titres ranging from 1Â10 11 to 1Â10 12 vg ml À1 ; HIV-1 titre of 5Â10 8 TU ml À1 ) were specifically chosen in order to increase the number of integration events and the possibility, therefore, of integration-related oncogenesis.
RESULTS AND DISCUSSION
Mice homozygous or heterozygous for various mutations in p53 develop a range of malignancies, principally lymphomas and sarcomas. In homozygotes these typically develop by 3-6 months of age and by B10 months in heterozygote animals. 36, 37, 39, 40 However, neither p53 À/À nor p53 +/À animals are known to spontaneously develop ocular tumours during their limited life span. To support the use of p53-knockout mice to evaluate the oncogenic potential of vectors, we initially sought to determine the capacities for, and relative susceptibilities of the different genotypes to malignant transformation induced by the intraocular administration of the carcinogen nickel subsulphide (Ni 3 S 2 ), which has been previously shown to induce a range of intraocular malignancies in rats. 41 Age-matched adult p53 À/À , p53 +/À and p53 +/+ mice on a mixed C57Bl10J/CBA background received single intravitreal injections of 100 mg Ni 3 S 2 . After Ni 3 S 2 administration, animals were examined twice weekly for signs of ocular or systemic malignancies or signs of distress, at which stage they were culled and the eyes processed for masked histological analysis. Animals were otherwise allowed to live to their natural lifespan to maximise the opportunity for the development of intraocular malignancies. p53 À/À mice displayed a substantially enhanced susceptibility to Ni 3 S 2 -induced tumourigenesis compared with p53 +/À and wildtype mice, which displayed a relatively low incidence of tumour induction ( Figure 1a ). Histologically, tumours consisted predominantly of malignant melanomas (Figure 1b) , although some eyes contained tumours having features of sarcoma. These results, therefore, indicate the potential for iatrogenic malignant transformation of quiescent or essentially quiescent retinal cells, and that this risk is significantly greater in the absence of p53. In one Ni 3 S 2 -injected p53 À/ À animal there was evidence of an ipsilateral periorbital sarcoma, but not of intraocular malignancy or scleral perforation, demonstrating that this tumour was not ocular in origin. Although an extraocular effect of Ni 3 S 2 cannot be excluded with certainty, this seems unlikely, in part due to the highly targeted nature of an intravitreal injection. It is more likely that the observed periocular tumour was part of a spectrum of sarcoma formation that spontaneously develops in these animals, as is seen in non-Ni 3 S 2 -injected animals. The 100 mg dose of Ni 3 S 2 , although successful in inducing malignancy, also resulted in varying severities of retinal toxicity, as manifested by outer and/or inner retinal degeneration in a substantial number of eyes independent of genotype.
As cell transduction is a pre-requisite for vector-induced malignant transformation by IM, assays for the protein products of the vectors used in this study were performed to demonstrate both in vivo transduction of, and expression within retinal tissue by the viral vectors after subretinal administration. A range of high-titre vectors were tested, including rAAV2/2 vectors delivering hrGFP under the control of the ubiquitous CMV promoter (rAAV.CMV.hrGFP) or delivering hRPE65 under the control of the RPE-specific hRPE65p promoter (rAAV.hRPE65p.hRPE65), and an integrating HIV-1 vector delivering hrGFP driven by the ubiquitous SFFV promoter (HIV-1.SFFV.hrGFP) (Figure 2a) . As cell viability is a requisite for malignant transformation, the reporter gene hrGFP was chosen in preference to more commonly used eGFP, as it appears to be less toxic to retinal cells after prolonged in vivo expression. 42, 43 An integrating lentiviral vector was chosen as its very high efficiency of integration would be expected to result in a large number of mutagenic events. In vivo reporter gene expression from the viral vectors delivering hrGFP was assayed using a combination of in vivo fundoscopy and post-mortem fluorescence microscopy of retinal cryosections. In vivo transduction and expression from subretinally administered rAAV.hRPE65p.hRPE65 vectors was confirmed by immunohistochemical detection of RPE65 protein in retinal cryosections from Rpe65 rd12/rd12 mice, which are naturally deficient for RPE65 protein. Figure 2b shows that after administration of rAAV.CMV.hrGFP, green (hrGFP) fluorescence was present in PR and RPE cells, indicating that both these cell types are transduced by this vector. In contrast, administration of HIV-1.SFFV.hrGFP resulted in efficient RPE-specific transduction. rAAV.hRPE65p.hRPE65-mediated RPE65 synthesis selectively in RPE cells after subretinal delivery, although it should be noted that as the specificity of transduction is a property of the vector type, rather than the incorporated promoter, it is very likely that this vector was also present in PRs, in addition to the RPE.
Having established the greater susceptibility of p53 À/À mice to iatrogenic ocular oncogenesis, these animals were used to determine the effect of gene therapy vectors upon the incidence of undesired transformation. rAAV or HIV-1 vectors were delivered subretinally to adult p53 À/À , p53 +/À or wild-type animals. p53 +/À animals, although less susceptible than p53 À/À mice, have a greater lifespan and were therefore also injected to assess the possibility that intraocular tumourigenesis could be a late process occurring beyond the typical shorter lifespan of p53 À/À mice. Uninjected animals were used to estimate both the background incidence of intraocular malignancy and the natural lifespan for each genotype. All animals were maintained and examined for tumours as described above. Using 4 ml of vector suspensions, the multiplicities of infection were estimated to be 900 (rAAV.CMV.hrGFP), 90 (rAAV.hRPE65p.hRPE65) and 6 (HIV-1.SFFV.hrGFP), respectively, as a mouse eye has B6.5Â10 6 PRs and 5Â10 5 RPE cells, 44 and as vector suspension is administered to B2/3 of the neurosensory retina and RPE using the subretinal injection method described. For the lentiviral vector the mean number of integration events should be similar to the multiplicities of infection. For rAAV vectors, an approximate integration frequency of 0.1% has been reported in the literature, 30, 33, 45 which suggests 0.9 and 0.09 integrations per cell for rAAV.CMV.hrGFP and rAAV.hRPE65p.hRPE65, respectively. We detected no histological evidence of intraocular malignancy in any of the vector-injected p53-deficient mice. A single animal from the rAAV.hRPE65p.hRPE65 group showed histological evidence of an extraocular tumour. This tumour was distinct from the ipsilateral eye, which had no signs of intraocular Figure 1 Histological characteristics and intraocular tumour incidence in Ni 3 S 2 -injected eyes. Age-matched animals of each genotype received intravitreal injections of a suspension containing 100 mg of the carcinogen Ni 3 S 2 , to determine the relative susceptibility of each genotype to intraocular oncogenic transformation. Eyes were retrieved from animals permitted to live to their natural lifespan to maximise the opportunity for clonal expansion, or retrieved upon the visible presence of ocular or systemic tumours or distress requiring humane euthanasia. Paraffin wax histological sections were prepared from Ni 3 S 2 -injected and genotype-matched uninjected eyes. (a) Examination of serial sections in a masked manner revealed a substantially greater incidence of intraocular malignancies in p53 À/À animals (n¼8/20; 40%) compared with either heterozygote (n¼1/22; 4.5%) or wild-type (n¼1/20; 5%) mice, confirming an enhanced propensity for iatrogenic malignant transformation. An extraocular probable sarcoma was identified in one p53 À/À animal. This was likely to be unrelated to the targeted intravitreal delivery of Ni 3 S 2 in this animal, which also did not display any signs of intraocular involvement. As these animals are prone to systemic sarcomatous proliferation, the presence of a periorbital malignant lesion was most like a consequence of this, rather than as a consequence of Ni 3 S 2 , although the latter possibility cannot be wholly excluded. Retinal toxicity, of varying severities, was however common throughout all injected groups, and is highly likely to be a direct adverse effect of the concentration of Ni 3 S 2 used in this study. (Table 1 and Figures 3 and 4) . It might be argued that the shorter lifespan of mice hampers a meaningful assessment of the oncogenic risk of gene therapy in the clinic. However, the cell populations transduced after subretinal administration (PRs and RPE) are quiescent, and hence there is no proliferation that would lead to the accumulation of further mutagenic hits over time. In non-dividing cells, the transformation of transduced cells will depend on acquisition of a second mutagenic hit, which in our model is already present in the form of p53 deficiency. The tumourigenesis occurring after Ni 3 S 2 administration indicates In vivo reporter gene expression from the viral vectors delivering hrGFP was assayed using a combination of post-mortem fluorescence microscopy of retinal cryosections, and by in vivo fundoscopy. Top panels from a representative p53 +/+ eye demonstrate long-term hrGFP expression predominantly in PRs, with a lower efficiency in RPE cells 12 month following subretinal delivery of AAV.CMV.hrGFP (4Â10 9 vg per eye). Lower panels depict efficient RPE-cell-specific hrGFP fluorescence in a representative p53 À/À mouse 73 days after delivery of HIV.SFFV.hrGFP (2Â10 6 TU per eye). Sustained expression with either vector was also confirmed by in vivo imaging 6 months following subretinal injection (right panels). (c) To confirm in vivo expression from the rAAV.hRPE65p.hRPE65 vector (4Â10 8 vg per eye), this vector was injected subretinally into Rpe65 rd12/rd12 mice, which are deficient in Rpe65, and eyes retrieved 8 weeks later. Retinal cryosections were immunostained for Rpe65 (green) and counterstained with propidium iodide (red). Rpe65 immunolabelling is clearly demonstrated in the RPE layer of wild-type mice, and with lower intensity in treated Rpe65 rd12/rd12 mice. Rpe65 is not detected in sections from rAAV.hRPE65p.hRPE65-injected Rpe65 rd12/rd12 mice incubated without primary antibody nor in uninjected Rpe65 rd12/rd12 mice. Some background fluorescence from the secondary antibody is visible in the choroid and sclera in all sections. cho, choroid; CMV, cytomegalovirus promoter; cPPT, central polypurine tract; inl, inner nuclear layer; is, inner PR segments; ITR, inverted terminal repeat region; LTR, long terminal repeat; onl, outer nuclear layer; os, outer PR segments; rpe, retinal pigment epithelium; SFFV, spleen focus forming virus promoter, WPRE, Woodchuck post-regulatory element.
rAAV or HIV-1 vectors do not induce eye tumours KS Balaggan et al that p53-deficiency is indeed sufficient to lead to ocular tumour formation within the lifespan of the animal.
There are two studies that have assessed iatrogenic malignant transformation after rAAV gene therapy in animal models that exhibit increased tumour incidence. In mucopolysaccharidosis type VII mice, Donsanto et al. 5, 7 discovered an increased incidence of liver tumours after systemic administration of rAAV vectors, a finding supported by specific rAAV genomic integration analyses, and concluded that administration of rAAV could lead to malignant transformation. On the other hand, Bell et al. 6 looked at tumour incidence in an ornithine transcarbamylase-deficient mouse model with and without rAAV gene therapy. They did not detect an increase in tumourigenesis, and found a lower vector copy number in the tumour tissue than in the healthy liver tissue. This led them to conclude that administration of rAAV does not lead to iatrogenic malignant transformation. A major difference between these studies and our work is the absence of spontaneous ocular tumours in the p53-deficient mice, even though these mice are more prone to the induction of ocular tumours as shown by the presence of tumours after Ni 3 S 2 injection. Although previous studies measured changes to a high frequency of spontaneous tumours, this current study directly assessed the number of malignant events induced by viral vector transduction.
The integration patterns of lentiviral vectors suggest that the risk of IM may be lower than that using vectors derived from simple retroviruses, such as those used in the X-SCID clinical trials. 46 Recent work using integrating HIV-1 vectors 14 also points to a lower risk in nondividing cells compared with dividing cells, a consequence of more favourable integration patterns associated with a substantially lower mitotic activity. Although the intraocular integration frequencies and integration patterns of rAAV2/2 vectors remain to be determined, these are also likely to be more favourable in non-dividing cells, as rAAV vectors appear to integrate preferentially at existing chromosomal breakage sites, 34 which would be expected to occur much less frequently in mitotically inactive cells. Together, these results therefore indicate that the risks of rAAV and even lentiviral vector delivery leading to malignant transformation of RPE or PR cells is likely to be very small. Future integration site analyses using the recently described Figure 3 PCR analyses of extraocular and systemic tumours from animals receiving subretinal injections of recombinant vectors. A single p53 À/À mouse that received subretinal rAAV.hRPE65p.hRPE65 vector displayed evidence of an extraocular tumour, but without any signs of intraocular malignancy or scleral perforation. Laser-capture microdissection of these malignant cells was performed, and cells were processed for PCR detection of RPE65 and control beta actin genes. Systemic tumours arising in rAAV.hRPE65p.hRPE65 and HIV-1.CMV.hrGFP vector-injected animals were also analysed for vector sequences using primers to detect RPE65 (500 bp), hrGFP (100 bp) or control beta actin (100 bp) genes (bands from two representative eyes from each vector group are shown). RPE65 and hrGFP plasmids were used as positive controls for RPE65 and hrGFP PCR reactions, respectively. No rAAV or HIV-1 vector sequences were detected in any of the extraocular or systemic tumour samples analysed, thereby excluding vector integration as being causal in their development. Age at the time of killing  Mean  476  520  460  461  195  161  223   Standard deviation  112  51  98  103  106  49  159  Median  499  523  491  464  171  156  155   25th percentile  414  480  420  436  136  125  109   75th percentile  548  544  518  524  218  188  339  Interquartile range  134  64  98  88  82  63  230 Statistical test (P-value) Mann-Whitney (P¼0. In patients, the incidence of malignancies increases with longevity. In this study, animals were, therefore, permitted to live to their natural lifespan to maximise the opportunity for malignant transformation and oncogenesis. This was also important as the integration of episomal rAAV DNA is typically a passive low-frequency event, in contrast to rapid and highly efficient lentiviral vector integration due to viral integrase. The prevalence of rAAV-involving integration events, a requisite for insertional mutagenesis, is likely therefore to increase with time. Animals were killed upon any macroscopic signs of ocular or systemic malignancies, or animal distress. Statistical normality tests demonstrated that not all lifespan data were normally distributed. Therefore, non-parametric statistical analyses, including correcting for multiple comparisons, were performed to evaluate for significant differences compared with uninjected animals. Vector-injected animals had no significantly different life spans compared with their genotype-matched uninjected counterparts. Retrieved eyes were processed for either paraffin wax or cryohistology. Histological sections were prepared and analysed as before, and showed no microscopic evidence of malignancies in any eyes. Furthermore, the lack of spontaneous tumours in uninjected p53-deficent animals even upon extended follow-up, further suggests that these animals do not develop malignancies of ocular cells in the absence of a second mutagenic stimulus.
technique of non-restrictive linear amplification-mediated PCR (LAM-PCR) should allow for superior unbiased detection of vectorhost junctions in both experimental and clinical samples, and provide for an enhanced understanding of the frequency, location and potential consequences of insertional events due to gene delivery. 47 rAAV integration also appears to be enhanced in the absence of p53 via uncertain mechanisms, although this might be mediated by p53 interactions with a functioning Rep protein, 48 which is not encoded in the rAAV vectors used in the current study. The absence of malignancies after subretinal administration of a range of high-titre vectors in an animal model that is defective in a major apoptosis pathway, possesses a heightened susceptibility to intraocular oncogenesis and that may possibly also permit higher levels of rAAV integration, suggests that any vector-chromosomal insertional events arising from subretinal vector delivery appear insufficient to induce uncontrolled clonal proliferation. The development of such adverse effects in naturally quiescent retinal cells is likely to require a high degree of integration in pro-oncogenic loci, particularly in the presence of functioning p53. The findings of this study further support the continued development of rAAV and lentiviral vectors for ophthalmic applications, in particular for the treatment of retinal diseases, and add to the growing body of evidence that these vectors are safe for clinical use in this context.
MATERIALS AND METHODS
Vector production and titration rAAV.CMV.hrGFP (1Â10 12 vg ml À1 ) and rAAV.hRPE65p.hRPE65 (1Â10 11 vg ml À1 ) vector production and titration have been previously described. 49 VSV-G pseudotyped HIV-1.SFFV.hrGFP vectors (5Â10 8 TU ml À1 ) were generated and titrated as previously described. 24 
Intraocular injections
The p53-knockout animals utilised in this study have been previously described. 36, 39, 50 All procedures on animals were approved by the local UCL Institute of Ophthalmology Ethics Committee and licensed by the United Kingdom Home Office. Animals were anaesthetised and pupillary mydriasis achieved as previously described. 42 For Ni 3 S 2 tumour-induction experiments, age-matched adult p53 À/À , p53 +/À and p53 +/+ mice on a mixed C57Bl10J/CBA background received single intravitreal injections of a suspension containing phosphate buffered saline and 100 mg Ni 3 S 2 . (CAS Number: 12035-72, Sigma Aldrich, Gillingham, UK) via a 10-mm 34-gauge needle mounted on a 5-ml Hamilton syringe (Hamilton Bonaduz AG, Bonaduz, Switzerland). For subretinal vector administration, 2 ml of vector suspension was delivered to each retinal hemisphere (4 ml total per eye) of adult mice as previously described. This method results in vector delivery to approximately two-thirds of the mouse retina. 42 Detection of transgene expression hrGFP fluorescence was detected by fluorescence microscopy of cryosections, similar to the method described for eGFP detection. 42 Briefly, eyes from each hrGFP vector-injected group were retrieved at various intervals following administration, and fixed overnight in 4% paraformaldehyde at 4 1C. Eyes were cryoprotected using 10% sucrose in phosphate buffered saline for 20 min and embedded in optimum cutting temperature medium (OCT, Sakura Finetek Europe BV, Zoeterwoude, The Netherlands). Eyes were serially sectioned at 12 mm thickness, and sections counterstained with Hoechst 33342, mounted in aqueous mounting medium (DakoCytomation, Glostrup, Denmark), and viewed using fluorescence microscopy. In vivo retinal imaging of hrGFP fluorescence was performed as previously described 42 at various intervals following subretinal injection of hrGFP-containing vectors using a human ophthalmic slit lamp (Keeler SL-16, Keeler Ltd, Windsor, UK) modified for obtaining colour and fluorescent images of rodent retinas. Immunostaining for RPE65 was performed on 4% paraformaldehyde-fixed 12 mm thick propidium iodide-counterstained cryosections, and RPE65 immunofluorescence detected using fluorescence microscopy as previously described. 24 
Examination for intraocular malignancy
All animals were maintained until their natural lifespan or until there were signs of distress, or macroscopic signs of ocular or systemic tumours. At these stages eyes from each group were retrieved, fixed in 10% formalin, processed overnight in a Leica Histokinette processor and embedded in paraffin wax. Eyes were serially sectioned at 5 mm thickness, mounted onto polylysine-coated slides, stained with haematoxylin and eosin, and examined in a masked manner by light microscopy, including by an experienced ophthalmic histopathologist, for intraocular or extraocular neoplastic cells.
Laser-capture tissue microdissection and PCR analyses 20 mm thick paraffin sections from the rAAV.hRPE65.hRPE65-injected animal were collected on PEN-membrane-coated slides NF 1.0 (ZEISS Ltd, Welwyn Garden City, UK), and transformed cells were collected using a PALM Robomover Axiovert 200 microscope (ZEISS Ltd). Approximately 300 extraocular tumour cells were laser-cut and catapulted into a silicon-embedded AdhesiveCap Eppendorf tube (ZEISS Ltd). Cells were lysed immediately and genomic DNA extraction was performed using the All Prep Extraction Kit (Qiagen Ltd, Crawley, UK) following the manufacturer's instructions. Genomic DNA was also extracted from flash-frozen samples of systemic tumours harvested at the time of death from the animals receiving intraocular rAAV or HIV-1 vectors. In all, 50 ng of genomic DNA (or plasmid for positive control) were used in PCR reactions with primers specific for beta-actin, RPE65 and hrGFP genes. Cycling conditions: 95 1C for 15 s, 57 1C for 10 s, 72 1C for 30 s; 35 cycles. Beta-actin forward: 5¢-GGAGGGGGTTGAGGTGTT-3¢. Beta-actin reverse: 5¢-T GTGCACTTTTATTGGTCTCAAG-3¢. hrGFP forward: 5¢-AGGACTTCCCCGA GTACCAC-3¢. hrGFP reverse: 5¢-BGTCCTCCACGTAGGTCTTC-3¢. hRPE65 forward: 5¢-GAACTGTCCTCGCCGCTCAC-3¢. hRPE65 reverse: 5¢-TCAAT GTGGGGGTGAGCAGTG-3¢.
Statistical analyses
Normality tests (Shapiro-Wilk, and D'agostino and Pearson omnibus tests) demonstrated non-Gaussian distributions of longevity data. Unpaired non-parametric statistical tests (Mann-Whitney U-tests for single comparison) or non-parametric one-way analysis of variance tests (Kruskal-Wallis tests and Dunn's post-tests for multiple comparisons) were used to analyse for statistically significant differences (Po0.05) in lifespan between vector-injected and uninjected control animals of each genotype. 
